Latest News

A recap of 7 standout interviews from LEADderm 2026, covering molluscum care, HS pipeline data, precision medicine, and dermatology leadership.

Alexander Combes, PhD, discusses how kidney organoids could be used to screen and repurpose drugs for acute kidney injury.

SWIFT accelerated Deep TMS resolved suicidal ideation faster than standard dosing, Owen Muir, MD, says.

Catch up on data from some of the most impactful trials presented at the European Society of Cardiology Congress 2026.

Human kidney organoids reveal why proximal tubule cells resist full recovery after AKI, aiding drug screening research.

SPY003 cut histologic disease activity by 10 points at 12 weeks, completing proof-of-concept for Spyre's IBD combinations.

David T. Rubin, MD, on the screening tools, direct questions, and therapy choices behind IBD's three tiers of remission.

Deucrictibant XR reduced HAE attack rates by 83% versus placebo in the pivotal phase 3 CHAPTER-3 study across all 3 HAE types.

The FDA granted DT120 (lysergide) ODT Breakthrough Therapy designation for MDD, citing promising phase 3 Emerge data.

Abbott's dual-energy PFA/RF ablation catheter met its primary effectiveness and safety endpoints in the 12-month FlexPulse IDE study behind its FDA nod.

Ross Levy, MD, on how Skin Angels invests in dermatology innovation and where he sees the field heading over the next 5 - 10 years.

Semaglutide was linked to fewer asthma attacks and COPD flare-ups than sulfonylureas, with no effect seen for other GLP-1 therapies.

Sciurba, of University of Pittsburgh, discusses full phase 3 OBERON and TITANIA results, including stronger responses in current smokers.

The oral STAT6 degrader achieved deep STAT6 suppression, up to 63% EASI reduction, and gains in asthma and rhinitis scores by week 4.

Hurst discusses data showing durably raised protective AAT levels in patients with alpha-1 antitrypsin deficiency.

At ERS 2026, John Oppenheimer, MD, discusses how PERFORM supports earlier escalation in patients with uncontrolled, infrequently exacerbating asthma.

ADVANCE Outcomes at ERS 2026 demonstrated improved odds of improvement and reduced odds of worsening.

The oral RARβ/γ agonist improved FVC and reduced fibrotic biomarkers over 12 weeks in a phase 2a trial presented at the ERS Congress 2026.

A COPD genetic risk score was linked to reduced lung function growth from birth to age 6, but only in children with high air pollution exposure.

Kyle Hogarth, MD, urges physicians to complete Alpha-1 testing during every COPD or asthma workup, warning that skipped tests delay diagnosis.

Novartis announced pelacarsen did not meet its primary endpoint in the phase 3 Lp(a)HORIZON cardiovascular outcomes trial despite Lp(a) lowering.

Paired airway and tissue sampling from 100 patients found greater microplastic burden in those with lung cancer.

Ross Levy, MD, explains why the LEADderm Skin Angels panel matters and what dermatology innovation looks like in daily practice.